Summary
Regeneron Pharmaceuticals, Inc. (REGN) announced on September 9, 2016, the appointment of two new independent directors to its Board: Dr. Bonnie L. Bassler and Dr. Huda Y. Zoghbi. These appointments are intended to fill existing vacancies and are effective until the 2017 Annual Shareholder Meeting. Both directors bring significant scientific expertise, with Dr. Bassler being a renowned molecular biologist and Dr. Zoghbi a leading expert in neurobiology and genetics. These new appointments are part of the company's ongoing governance strategy. Both directors will receive standard compensation for non-employee directors, including annual retainers and stock options. Investors should note that these additions to the board signal a continued focus on strong scientific leadership and oversight as Regeneron advances its pipeline. The company did not disclose any specific strategic initiatives tied to these appointments, but the caliber of the appointees suggests a commitment to robust scientific and governance practices.
Key Highlights
- 1Regeneron appointed two new independent directors, Dr. Bonnie L. Bassler and Dr. Huda Y. Zoghbi, to its Board of Directors.
- 2The appointments were made to fill existing vacancies on the Board.
- 3Both new directors will serve until the 2017 Annual Shareholder Meeting.
- 4Dr. Bassler and Dr. Zoghbi have been appointed to the Corporate Governance and Compliance Committee and the Technology Committee, respectively.
- 5New directors will receive compensation in line with the company's non-employee director practices, including an annual retainer of $55,000 and an additional $10,000 per committee.
- 6Each new director was granted an option to purchase 15,353 shares of common stock upon election.
- 7There are no arrangements or understandings with other parties related to the selection of these new directors.